S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
The Battery Metal Nobody Told You About (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Bolt Biotherapeutics Stock Price, News & Analysis (NASDAQ:BOLT)

$0.93
+0.02 (+2.20%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.92
$0.95
50-Day Range
$0.85
$1.07
52-Week Range
$0.84
$2.03
Volume
227,845 shs
Average Volume
163,647 shs
Market Capitalization
$35.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Bolt Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
509.3% Upside
$5.67 Price Target
Short Interest
Bearish
6.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.66mentions of Bolt Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$125,191 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.78) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

390th out of 948 stocks

Biotechnology Industry

12th out of 46 stocks


BOLT stock logo

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BOLT Stock Price History

BOLT Stock News Headlines

U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
Bolt Biotherapeutics Inc Ordinary Shares BOLT
U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
US0977021049.SG - Bolt Biotherapeutics Inc.
Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright
BOLT.O - | Stock Price & Latest News | Reuters
Bolt Biotherapeutics Inc Ordinary Shares
See More Headlines
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+509.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-88,100,000.00
Net Margins
-990.43%
Pretax Margin
-990.43%

Debt

Sales & Book Value

Annual Sales
$5.73 million
Book Value
$4.55 per share

Miscellaneous

Free Float
27,184,000
Market Cap
$35.32 million
Optionable
Not Optionable
Beta
0.71
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 68)
    CEO & Director
    Comp: $829.32k
  • Dr. Edgar George Engleman M.D. (Age 77)
    Founder & Independent Director
    Comp: $38.75k
  • Mr. William P. QuinnMr. William P. Quinn (Age 52)
    CFO & Secretary
    Comp: $594.56k
  • Mr. Grant Yonehiro C.F.A. (Age 59)
    M.B.A., Chief Business Officer
    Comp: $544.71k
  • Dr. Edith A. Perez M.D. (Age 66)
    Chief Medical Officer
    Comp: $668.32k
  • Mr. Wesley Burwell
    VP & Head of Human Resources
  • Dr. Nathan Ihle Ph.D.
    Senior Vice President of Pharmaceutical Operations














BOLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLT shares.
View BOLT analyst ratings
or view top-rated stocks.

What is Bolt Biotherapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12-month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 509.3% from the stock's current price.
View analysts price targets for BOLT
or view top-rated stocks among Wall Street analysts.

How have BOLT shares performed in 2023?

Bolt Biotherapeutics' stock was trading at $1.30 at the start of the year. Since then, BOLT shares have decreased by 28.5% and is now trading at $0.9301.
View the best growth stocks for 2023 here
.

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BOLT earnings forecast
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.06. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $1.60 million. Bolt Biotherapeutics had a negative net margin of 990.43% and a negative trailing twelve-month return on equity of 47.56%.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Newtyn Management LLC (2.69%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP, Vivo Capital Viii, Llc and William P Quinn.
View institutional ownership trends
.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BOLT) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -